HFGL1-Fc fusion protein and application thereof
By connecting hFGL1 to the IgG-Fc segment and preparing hFGL1-Fc fusion protein, the shortcomings of rheumatoid arthritis treatment, especially the problem of joint damage inhibition, achieved significant therapeutic effects in mouse models, including reducing inflammation It has bone erosion and no liver toxic side effects.
Patent Information
- Application Number
- CN202310578507.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-22
- Publication Date
- 2024-11-22
AI Technical Summary
There is a lack of effective treatment of rheumatoid arthritis (RA) in the prior art, especially methods to inhibit joint damage, and the immune function of hFGL1 in RA has not been fully studied.
A hFGL1-Fc fusion protein developed by ligating human fibrinogen-like protein 1 (hFGL1) with the human IgG-Fc segment and purified in the HEK293 cell expression system for use as a potential RA therapeutic target using it Anti-inflammatory and immune-regulating effects.
In collagen-induced arthritis model mice, hFGL1-Fc fusion protein significantly improves arthritis symptoms, reduces the expression of inflammatory factor TNF-α, reduces bone erosion, and has no toxic side effects on the liver, providing experimental basis for new targeted RA treatment. .
Smart Images

Figure CN118994413A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and specifically relates to the field of treating autoimmune diseases by connecting human fibrinogen-like protein 1 (hFGL1) and human IgG-Fc segment and expressing and purifying the prepared hFGL1-Fc fusion protein, and in particular relates to an hFGL1-Fc fusion protein and a use thereof. Background Art
[0002] Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease that affects more than 1% of the total population. The cause of RA is still unclear, and its main characteristics are persistent synovial inflammation and joint damage. In the late stage, patients may experience joint deformities and severe disability, accompanied by widespread joint pain. The treatment of RA has made great progress in recent years. The most widely used therapy is to use anti-inflammatory drugs alone or in combination with immunosuppressants to inhibit inflammatory responses to relieve symptoms such as pain. However, there is still no specific drug for its treatment. How to effectively inhibit or even reverse joint damage in RA patients remains a world-class problem.
[0003] Human Fibrinogen-like Protein 1 (hFGL1) belongs to the fibrinogen family and is mainly secreted by hepatocytes. hFGL1 is a key "bridge" between liver regeneration and adipose tissue function. hFGL1 plays an important role in cancer and is a potential target for cancer treatment. In the past few years, a series of new evidences have shown that hFGL1 has immunomodulatory effects as a new effector molecule. The immune function of hFGL1 is mainly reflected in binding to LAG-3 and weakening CD8 + The cytotoxic effect of T cells promotes tumor growth. At present, the research on hFGL1 is mainly to study its basic role in tumors and immunity. Although hFGL1 is related to tumor treatment, it is limited to basic research and lacks further experimental results and clinical research reports. It can be used as a biomarker for diagnosis and prognosis. Fc fusion protein refers to a new type of protein produced by fusing the Fc segment of immunoglobulin IgG with a functional protein molecule (hFGL1) with biological activity using genetic engineering technology. The hFGL1-Fc fusion protein not only has the potential to exert the biological activity of the fused protein, but also has some characteristics of antibodies, such as causing antibody-dependent cell-mediated cytotoxicity (ADCC).
[0004] So far, there are few studies on the effect of hFGL1 on RA, and more importantly, the immune function of hFGL1 is still unknown. Based on the existing literature reports and the previous experimental results of the research team, the applicant will explore the inhibitory effect of hFGL1-Fc fusion protein in the pathogenesis of RA, providing a theoretical basis for the development of potential new therapeutic targets for RA. Summary of the invention
[0005] In order to solve the deficiencies in the prior art, the present invention aims to provide a hFGL1-Fc fusion protein and uses thereof.
[0006] The specific technical solutions of the present invention are as follows:
[0007] In a first aspect, the present invention provides an hFGL1-Fc fusion protein, wherein the fusion protein comprises human fibrinogen-like protein 1 and the Fc segment of human IgG, and the amino acid sequence of the human fibrinogen-like protein 1 is shown in SEQ ID NO.3.
[0008] Furthermore, the amino acid sequence of the Fc segment of human IgG is shown in SEQ ID NO.4.
[0009] Furthermore, the C-terminus of the human fibrinogen-like protein 1 is connected to the Fc segment of the human IgG, and the amino acid sequence of the fusion protein is shown in SEQ ID NO.2.
[0010] Furthermore, an IgK signal peptide is fused to the N-terminus of the fusion protein.
[0011] The present invention also provides a gene encoding the fusion protein.
[0012] Furthermore, the nucleotide sequence of the gene is shown in SEQ ID NO.1.
[0013] The present invention also provides biological materials expressing the fusion protein or containing the gene, wherein the biological materials include at least one of an expression cassette, a vector, a recombinant microorganism or a cell line.
[0014] The present invention also provides a method for preparing the fusion protein, and the gene encoding the fusion protein is expressed in a HEK293 cell expression system.
[0015] The present invention also provides the use of the fusion protein in any of the following:
[0016] (1) Preparation of drugs for preventing and / or treating rheumatoid arthritis;
[0017] (2) preparing drugs for preventing and / or treating inflammatory reactions associated with rheumatoid arthritis;
[0018] (3) preparing a drug for preventing and / or treating synovial inflammation associated with rheumatoid arthritis;
[0019] (4) Preparation of drugs for preventing and / or treating joint swelling or joint damage caused by rheumatoid arthritis.
[0020] The present invention also provides a pharmaceutical composition, wherein the active ingredient of the pharmaceutical composition includes the fusion protein.
[0021] The beneficial effects of the present invention are:
[0022] The present invention provides an hFGL1-Fc fusion protein, and proves that it can be used as an anti-inflammatory agent for the treatment of rheumatoid arthritis. The hFGL1-Fc fusion protein has a good therapeutic effect in collagen-induced arthritis model mice, can improve the bone erosion caused by CIA mice, mainly the swelling and damage of the soles and ankle joints of mice, can reduce the expression level of the inflammatory factor TNF-α in the serum of mice, has no potential toxic side effects on the liver, and can significantly increase the reduction of Tb.N; Tb.Th; Tb.sp; BV / TV parameters caused by the CIA group. The development of hFGL1-Fc fusion protein provides an experimental basis for new targeted therapeutic drugs with high selectivity for the treatment of RA. Specifically:
[0023] The present invention reveals the therapeutic effect of hFGL1-Fc fusion protein on RA, as well as the effective dose of the protein and related action mechanisms through the collagen induced arthritis (CIA) model of DBA / 1J male mice caused by bovine type II collagen.
[0024] At D24 of the experimental modeling, the paws of mice showed redness and swelling. Injection of hFGL1-Fc fusion protein (4,8 mg / kg) by tail vein and oral administration of the positive drug methotrexate MTX (2 mg / kg) significantly reduced the arthritis index of CIA mice. At D56, after the mice were euthanized, the livers were taken and HE staining was performed to observe the pathological changes of the tissues. The liver pathology results showed that no inflammatory cell infiltration was observed in all groups, indicating that there were no obvious toxic side effects on the liver.
[0025] At D56, after the mice were euthanized, the left hind paw was taken for Micro-CT scanning and 3D imaging to observe the damage of the left hind paw and statistically analyze the bone erosion related parameters. The 3D scanning results showed that after treatment with hFGL1-Fc fusion protein and MTX, the bone erosion of the mouse paw was improved. Compared with the Normal group, the Tb.N; Tb.Th; Tb.sp; BV / TV of the CIA group mice were significantly reduced. After treatment with hFGL1-Fc fusion protein, the reduction of Tb.N; Tb.Th; Tb.sp; BV / TV parameters caused by the CIA group could be significantly increased.
[0026] D56, after the mice were euthanized, the mouse serum was taken for inflammatory factor TNF-α ELISA detection. Compared with the CIA group, the 4 mg / kg and 8 mg / kg fusion protein groups could significantly reduce the expression level of inflammatory factors, among which the 4 mg / kg fusion protein reduced the level of inflammatory factors more significantly than the positive drug methotrexate group. Description of the drawings:
[0027] Figure 1 This is the expression diagram of hFGL1-Fc fusion protein.
[0028] Figure 2 The figure is the result of arthritis scoring of mice. They were divided into normal group, model group (CIA group), low-dose fusion protein administration group (4 mg / kg), high-dose fusion protein administration group (8 mg / kg), and positive drug methotrexate MTX (2 mg / kg) administration group.
[0029] Figure 3 The figure shows the swelling degree of the paw and ankle joint of mice. The mice were divided into a normal group, a model group (CIA group), a low-dose fusion protein administration group (4 mg / kg), a high-dose fusion protein administration group (8 mg / kg), and a positive drug methotrexate MTX (2 mg / kg) administration group.
[0030] Figure 4 The 3D images of the left hind paw of mice after Micro-CT scanning were divided into normal group, model group (CIA group), low-dose fusion protein administration group (4 mg / kg), high-dose fusion protein administration group (8 mg / kg), and positive drug methotrexate MTX (2 mg / kg) administration group.
[0031] Figure 5 The figure shows the bone parameter statistics of the left hind paw of mice after Micro-CT scanning. The mice were divided into normal group, model group (CIA group), low-dose fusion protein administration group (4 mg / kg), high-dose fusion protein administration group (8 mg / kg), and positive drug methotrexate MTX (2 mg / kg) administration group.
[0032] Figure 6 The figure is a statistical chart of the concentration of TNF-α, a inflammatory factor in the serum of mice. The mice were divided into a normal group, a model group (CIA group), a low-dose fusion protein administration group (4 mg / kg), a high-dose fusion protein administration group (8 mg / kg), and a positive drug methotrexate MTX (2 mg / kg) administration group.
[0033] Figure 7 The HE staining image of mouse liver was divided into normal group, model group (CIA group), low-dose fusion protein administration group (4 mg / kg), high-dose fusion protein administration group (8 mg / kg), and positive drug methotrexate MTX (2 mg / kg) administration group. DETAILED DESCRIPTION
[0034] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, these embodiments are merely exemplary and do not constitute any limitation to the scope of the present invention.
[0035] Unless otherwise specified, the reagents and consumables used in the following examples can be obtained from commercial sources.
[0036] If no specific techniques or conditions are specified in the examples, they can be carried out according to the techniques or conditions described in the literature in the art or according to the product instructions.
[0037] Example 1 Preparation of hFGL1-Fc fusion protein
[0038] 1. Expression and purification of hFGL1-Fc fusion protein
[0039] First, the nucleotide sequence of the fusion protein in this embodiment is obtained by mammalian cell codon optimization (as shown in SEQ ID NO.1), and the gene synthesized by mammalian cell codon optimization is inserted into the pCMV3 expression vector containing the CMV promoter, and the IgK signal peptide is fused at the N-terminus for secretory expression. The mature high-density suspension HEK293 cell expression system is used for protein expression. The expression conditions are optimized to obtain the most suitable expression environment. The expression parameters are first optimized in a vial, including expression time, temperature, and transfection reagent. Subsequently, the culture is expanded according to the most suitable expression conditions. The present invention uses a density of 4-5×10 6 HEK293 cells with a viability of more than 95% were transiently transfected with plasmids at a mass ratio of 1:3 between the plasmid and the transfection reagent PEI, and downstream protein purification was performed on the seventh day.
[0040] Protein A chromatography filler was used for purification. After 7 days, the cell supernatant was collected by centrifugation and mixed with 150mM NaCl, 25mM NaH 2 PO4 , 6 mL of Protein A filler was incubated on a shaker at room temperature for 1 h. After 1 h, the supernatant was filtered and washed with 150 mM NaCl, 25 mM NaH 2 PO 4 Precooled Bindingbuffer 50mL was used to bind Protein A filler, and then eluted with precooled Elutionbuffer 8, 12, and 12mL containing 0.1M glycine at pH = 3. During elution, neutralization buffer (150mM NaCl, 60mM Tris pH = 8.0) corresponding to Elutionbuffer was added to each centrifuge tube. 10μL of the protein collected in each tube was added to 5μL 1×SDS loading buffer and mixed thoroughly, and denatured in a metal bath at 105°C for 8min. The denatured protein was immediately used for SDS-PAGE gel electrophoresis, and the purity of the purified protein was identified by Coomassie Brilliant Blue staining.
[0041] Nucleic acid sequence of hFGL1-Fc fusion protein SEQ ID NO.1:
[0042]
[0043] Amino acid sequence of hFGL1-Fc fusion protein SEQ ID NO.2:
[0044] LEDCAQEQMRLRAQVRLLETRVKQQQVKIKQLLQENEVQFLDKGDENTVIDLGSKRQYADCSEIFNDGYKLSGFYKIKPLQSPAEFSVYCDMSDGGGWTVIQRRSDGSENFNRGWKDYENGFGNFVQKHGEYWLGNKNLHFLTTQEDYTLKIDLADFEKNSRYAQYKNFKVGDEKNFYELNIGEYSGTAGDSLAGNFHPEVQWWASHQRMKFSTWDRDHDNYEGNCAEEDQSGWWFNRCHSANLNGVYYSGPYTAKTDNGIVWYTWHGWWYSLKSVVMKIRPNDFIPNVIDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0045] Amino acid sequence of human fibrinogen-like protein 1 SEQ ID NO.3:
[0046] LEDCAQEQMRLRAQVRLLETRVKQQQVKIKQLLQENEVQFLDKGDENTVIDLGSKRQYADCSEIFNDGYKLSGFYKIKPLQSPAEFSVYCDMSDGGGWTVIQRRSDGSENFNRGWKDYENGFGNFVQKHGEYWLGNKNLHFLTTQEDYTLKIDLADFEKNSRYAQYKNFKVGDEKNFYELNIGEYSGTAGDSLAGNFHPEVQWWASHQRMKFSTWDRDHDNYEGNCAEEDQSGWWFNRCHSANLNGVYYSGPYTAKTDNGIVWYTWHGWWYSLKSVVMKIRPNDFIPNVI
[0047] The amino acid sequence of the Fc segment of human IgG is SEQ ID NO.4:
[0048] DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE KTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0049] Amino acid sequence of IgK signal peptide SEQ ID NO.5:MGWSCIILFLVATATGVH
[0050] 2. Experimental results
[0051] Figure 1 The Coomassie blue staining image of the purified hFGL1-Fc fusion protein. The molecular weight of the hFGL1-Fc fusion protein is about 62.7 kDa.
[0052] Example 2 In vivo pharmacodynamics study of hFGL1-Fc fusion protein on CIA mouse model
[0053] 1. Preparation of collagen-induced arthritis mouse model (CIA)
[0054] (1) Preparation of pre-immune reagents: a. 0.1 M glacial acetic acid: add 57 μL glacial acetic acid to 10 mL pure water to obtain a 0.1 M glacial acetic acid solution (prepare immediately before use and precool); b. Preparation of bovine type II collagen (CII): add 2 mL 0.1 M glacial acetic acid solution to 10 mg bovine type II collagen to obtain a 5 mg / mL CII solution (initial concentration).
[0055] (2) First immunization (D0): CII was 100 μg and ground with Freund's complete adjuvant (CFA) in a mortar on ice at a ratio of 1:1 until it became a milky white oil-in-water emulsion. The criterion for judging whether the grinding was successful was to add a drop of it to the water. If it did not spread immediately, it indicated that the grinding components were insufficient. The hair at the base of the mouse's tail was shaved with a shaver, and the immunization site was disinfected with an alcohol cotton ball. 100 μL of the emulsion was drawn with a 1 mL syringe, and the skin at the base of the tail was gently lifted and the needle was inserted into the skin (two injections were made at two locations). There would be a small bump at the injection site.
[0056] (3) Secondary immunization (D21): CII was mixed with complete Freund's adjuvant (CFA) at a ratio of 1:1 and ground on ice in a mortar until it became a milky white oil-in-water emulsion. 100 μL was injected at the base of the tail in the same manner as the first immunization.
[0057] (4) Experimental groups: The mice were divided into normal control group (Normal group), model group (CIA group), 4 mg / kg FGL1-Fc fusion protein treatment group, 8 mg / kg FGL1-Fc fusion protein treatment group, and 2 mg / kg methotrexate positive drug group (MTX group), with 6 mice in each group.
[0058] (5) Treatment after secondary immunization: Treatment began on the third day after the secondary immunization (D21), and the drug was administered 10 times via tail vein every three days from D24 to D53. Mice were killed on D56, and the liver, paws, and blood were collected for subsequent studies.
[0059] (6) Scoring: Starting from the third day after the second immunization, observe whether the toes and ankle joints of the front and rear paws of the mice are red and swollen. Scoring begins on the third day after immunization. If the toes and ankle joints are red and swollen, it is defined as arthritis. The scoring criteria are: no changes in redness and swelling (0 points), obvious redness and swelling of one toe (1 point), slight swelling of the ankle joint or redness and swelling of two toes (2 points), obvious redness and swelling of the ankle joint or more than two toes (3 points), redness and swelling of the entire sole of the foot, and joint stiffness (4 points). The maximum score for each mouse is 16 points.
[0060] 2. Micro-CT scanning detection
[0061] (1) At the end of the experiment, the mice were humanely killed, and the paws (above the ankle joint) were fixed in 4% paraformaldehyde at 4°C for 48 hours. The fixed paws were scanned using a Micro-CT scanner to form a 3D image. The scanning parameters were: voltage 80 kV, current 0.667 mA, resolution 20 μm, and scanning time 1 hour.
[0062] (2) Data analysis: After exporting the scanned 3D model, the data was analyzed to obtain the bone morphological parameters of each mouse.
[0063] 3. ELISA to detect the content of inflammatory factor TNF-α in serum
[0064] (1) Take out the panels required for testing from the sealed bag that has been equilibrated to room temperature.
[0065] (2) Add universal diluent for standards and specimens to the blank wells, and add specimens or standards of different concentrations (100 μL / well) to the other corresponding wells. Seal the reaction wells with sealing tape and incubate in a 37°C incubator in the dark for 90 min.
[0066] (3) Prepare the biotinylated antibody working solution 20 minutes in advance and wash the plate 5 times.
[0067] (4) Add biotinylated antibody diluent to the blank wells and add biotinylated antibody working solution (100 μL / well) to the remaining wells. Seal the reaction wells with new sealing tape and incubate in a 37°C incubator in the dark for 60 minutes.
[0068] (5) Prepare the enzyme conjugate working solution 20 minutes in advance. Place it at room temperature (22-25°C) away from light and wash the plate 5 times.
[0069] (6) Add enzyme conjugate diluent to the blank wells and add enzyme conjugate working solution (100 μL / well) to the remaining wells. Seal the reaction wells with new sealing tape and incubate in a 37°C incubator in the dark for 30 minutes.
[0070] (7) Turn on the ELISA reader, preheat the instrument, and set the test program. Wash the plate 5 times.
[0071] (8) Add 100 μL / well of chromogenic substrate (TMB) and incubate at 37°C in a dark incubator for 15 min.
[0072] (9) Add 100 μL / well of the reaction stop solution, mix well, and then measure the OD450 value (within 3 minutes).
[0073] IV. Experimental Results
[0074] (1) Rating results
[0075] Figure 2 The arthritis scores of mice in the normal group, model group (CIA group), low-dose fusion protein administration group (4 mg / kg), high-dose fusion protein administration group (8 mg / kg), and positive drug methotrexate MTX (2 mg / kg) administration group. Figure 2 It can be seen that the clinical score of arthritis in the mice treated with the fusion protein was significantly lower than that in the model group, thus proving that the fusion protein has a certain therapeutic effect on the mice in the CIA model group.
[0076] (2) Swelling of the paw and ankle joints
[0077] Figure 3 The left hind paws of mice in the normal group, model group (CIA group), low-dose fusion protein administration group (4 mg / kg), high-dose fusion protein administration group (8 mg / kg), and positive drug methotrexate MTX (2 mg / kg) administration group were shown in the figure after onset and treatment. Figure 3 It can be seen that at D56, the swelling degree of the hind paws and ankle joints of mice in the fusion protein treatment group was significantly lower than that in the model group.
[0078] (3) Micro-CT scanning of bone destruction in mouse hind paws
[0079] Figure 4 3D images of the left hind paws of mice after Micro-CT scanning in the normal group, model group (CIA group), low-dose fusion protein administration group (4 mg / kg), high-dose fusion protein administration group (8 mg / kg), and positive drug methotrexate MTX (2 mg / kg) administration group. Figure 5 The 3D scanning results showed that after treatment with FGL1-Fc protein and MTX, the bone erosion of the mouse paws was improved. Compared with the normal group, the Tb.N; Tb.Th; Tb.sp; BV / TV of the CIA group mice were significantly reduced, and after treatment with FGL1-Fc protein, the reduction of Tb.N; Tb.Th; Tb.sp; BV / TV parameters caused by the CIA group was significantly increased, indicating that the fusion protein can significantly reduce the bone erosion caused by CIA.
[0080] (4) Levels of TNF-α in serum
[0081] Figure 6 The figure shows the concentration of TNF-α in the serum of mice in the normal group, model group (CIA group), low-dose fusion protein administration group (4 mg / kg), high-dose fusion protein administration group (8 mg / kg), and positive drug methotrexate MTX (2 mg / kg) administration group. Figure 6 It can be seen that the level of TNF-α in the serum of mice in the fusion protein treatment group was significantly lower than that in the model group, indicating that the fusion protein can significantly reduce the expression level of the inflammatory factor TNF-α in the serum of mice, further illustrating the therapeutic effect of the fusion protein in CIA model mice.
[0082] (5) Effects of fusion protein on the liver
[0083] Figure 7 HE staining of mouse liver in the normal group, model group (CIA group), low-dose fusion protein administration group (4 mg / kg), high-dose fusion protein administration group (8 mg / kg), and positive drug methotrexate MTX (2 mg / kg) administration group. Figure 7 It can be seen that no abnormalities such as inflammatory cell infiltration were found in the liver of each group, indicating that the fusion protein has no potential toxic side effects on the liver.
[0084] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any equivalent changes made to the technical solutions of the present invention by ordinary technicians in this field after reading the specification of the present invention are covered by the claims of the present invention.
Claims
1. A hFGL1-Fc fusion protein, characterized in that: The fusion protein comprises human fibrinogen-like protein 1 and the Fc segment of human IgG. The amino acid sequence of the human fibrinogen-like protein 1 is shown in SEQ ID NO.
3.
2. The fusion protein according to claim 1, characterized in that The amino acid sequence of the Fc segment of human IgG is shown in SEQ ID NO.
4.
3. The fusion protein according to claim 1, characterized in that The C-terminus of the human fibrinogen-like protein 1 is connected to the Fc segment of the human IgG, and the amino acid sequence of the fusion protein is shown in SEQ ID NO.
2.
4. The fusion protein according to claim 1, characterized in that An IgK signal peptide is also fused to the N-terminus of the fusion protein.
5. A gene encoding the fusion protein according to any one of claims 1 to 4.
6. The gene according to claim 5, characterized in that The nucleotide sequence of the gene is shown in SEQ ID NO.
1.
7. A biological material expressing the fusion protein according to any one of claims 1 to 4, or containing the gene according to claim 5 or 6, characterized in that: The biological material includes at least one of an expression cassette, a vector, a recombinant microorganism or a cell line.
8. The method for preparing the fusion protein according to any one of claims 1 to 4, characterized in that: The gene encoding the fusion protein according to any one of claims 1 to 4 is expressed in a HEK293 cell expression system.
9. Use of the fusion protein according to any one of claims 1 to 4 in any one of the following: (1) Preparation of drugs for preventing and / or treating rheumatoid arthritis; (2) preparing drugs for preventing and / or treating inflammatory reactions associated with rheumatoid arthritis; (3) preparing a drug for preventing and / or treating synovial inflammation associated with rheumatoid arthritis; (4) Preparation of drugs for preventing and / or treating joint swelling or joint damage caused by rheumatoid arthritis.
10. A pharmaceutical composition, characterized in that The active ingredient of the pharmaceutical composition comprises the fusion protein according to any one of claims 1 to 4.
